Showing results (11-20 of 159) with videos related to
Sort By:
Pageof 16
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|September 29, 2004
Impaired glucose metabolism in patients with heart failure: pathophysiology and possible treatment strategiesAlexander Tenenbaum, Enrique Z FismanCardiovascular Diabetology|January 29, 2025
Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challengesFrancisco Westermeier, Enrique Z FismanCardiology Journal|May 17, 2013
The metabolic syndrome entanglement: Cutting the Gordian knotEnrique Z Fisman, Alexander TenenbaumCardiovascular Diabetology|June 25, 2014
Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?Enrique Z Fisman, Alexander TenenbaumCardiovascular Diabetology|June 17, 2010
"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid studyAlexander Tenenbaum, Enrique Z FismanCardiovascular Diabetology|August 30, 2018
Omega-3 polyunsaturated fatty acids supplementation in patients with diabetes and cardiovascular disease risk: does dose really matter?Alexander Tenenbaum, Enrique Z FismanCardiovascular Diabetology|July 22, 2009
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart diseaseEnrique Z Fisman, Alexander TenenbaumCardiovascular Diabetology|September 20, 2005
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessonsAlexander Tenenbaum, Michael Motro, Enrique Z FismanCardiovascular Diabetology|December 5, 2014
Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factorAlexander Tenenbaum, Robert Klempfner, Enrique Z FismanCardiovascular Diabetology|July 2, 2003
Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR)Alexander Tenenbaum, Enrique Z Fisman, Michael MotroPageof 16